Stimcell Energetics Files 8-K
Ticker: STME · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1493712
| Field | Detail |
|---|---|
| Company | Stimcell Energetics Inc. (STME) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, regulation-fd
TL;DR
Stimcell Energetics filed an 8-K on 12/02/25, standard disclosure.
AI Summary
Stimcell Energetics Inc. filed an 8-K on December 2, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Cell MedX Corp., is incorporated in Nevada and based in Vancouver, British Columbia.
Why It Matters
This filing indicates a regulatory disclosure and submission of financial documents, which is standard for public companies but provides insight into their current reporting status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for financial statements and Regulation FD disclosure, not indicating any specific adverse events.
Key Numbers
- 000-54500 — SEC File Number (Identifies the company's filing with the SEC.)
- 38-3939625 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Stimcell Energetics Inc. (company) — Registrant
- Cell MedX Corp. (company) — Former company name
- December 2, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- Vancouver, British Columbia (location) — Business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this 8-K filed?
The filing was made on December 2, 2025.
What was Stimcell Energetics Inc. previously named?
The company was formerly known as Cell MedX Corp.
In which state is Stimcell Energetics Inc. incorporated?
Stimcell Energetics Inc. is incorporated in Nevada (NV).
What is the business address of Stimcell Energetics Inc.?
The business address is 555 - 1130 Pender Street, West, Vancouver, British Columbia, V6E 4A4.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-12-02 17:00:17
Filing Documents
- stme-20251202_8k.htm (8-K) — 23KB
- stme_ex991.htm (EX-99.1) — 8KB
- stmeex991_1.jpg (GRAPHIC) — 79KB
- 0001493712-25-000005.txt ( ) — 237KB
- stme-20251202_def.xml (EX-101.DEF) — 2KB
- stme-20251202_lab.xml (EX-101.LAB) — 12KB
- stme-20251202_pre.xml (EX-101.PRE) — 8KB
- stme-20251202.xsd (EX-101.SCH) — 2KB
- stme-20251202_8k_htm.xml (XML) — 3KB
01 REGULATION FD DISCLOSURE
ITEM 7.01 REGULATION FD DISCLOSURE On December 2, 2025, StimCell Energetics Inc. (the "Company") issued an informational news release (the "Release") announcing the signing of a service agreement with the St. Boniface Hospital Albrechtsen Research Centre, to explore the effects of the Company's proprietary eBalance device on mitochondrial function in cultured sensory neurons to further define the physiological action of microcurrents. A copy of the Release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits The following exhibits are provided with this Current Report: Exhibit Number Description of Exhibit 99.1 News release dated December 2, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STIMCELL ENERGETICS INC. Date: December 2, 2025 By: /s/ David Jeffs David Jeffs, Chief Executive Officer 3